98%
921
2 minutes
20
Background: Detailed information on the profile of patients with Brugada syndrome (BrS) presenting their first arrhythmic event (AE) after prophylactic implantation of an implantable cardioverter-defibrillator (ICD) is limited.
Objectives: The objectives of this study were (1) to compare clinical, electrocardiographic, electrophysiologic, and genetic profiles of patients who exhibited their first documented AE as aborted cardiac arrest (group A) with profiles of those in whom the AE was documented after prophylactic ICD implantation (group B) and (2) to characterize group B patients' profile using the class II indications for ICD implantation established by HRS/EHRA/APHRS expert consensus statement in 2013.
Methods: A survey of 23 centers from 10 Western and 4 Asian countries enabled data collection of 678 patients with BrS who exhibited their AE (group A, n = 426; group B, n = 252).
Results: The first AE occurred in group B patients 6.7 years later than in group A (mean age 46.1 ± 13.3 years vs 39.4 ± 15.1 years; P < .001). Group B patients had a higher incidence of family history of sudden cardiac death and SCN5A mutations. Of the 252 group B patients, 189 (75%) complied with the HRS/EHRA/APHRS indications whereas the remaining 63 (25%) did not.
Conclusion: Patients with BrS with the first AE documented after prophylactic ICD implantation exhibited their AE at a later age with a higher incidence of positive family history of sudden cardiac death and SCN5A mutations as compared with those presenting with aborted cardiac arrest. Only 75% of patients who exhibited an AE after receiving a prophylactic ICD complied with the 2013 class II indications, suggesting that efforts are still required for improving risk stratification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hrthm.2018.01.014 | DOI Listing |
Eur J Case Rep Intern Med
August 2025
Internal Medicine and Hypertension Center, Sant'Anna Hospital Castelnovo ne' monti, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Unlabelled: Brugada syndrome (BrS) is a disorder leading to potentially life-threatening ventricular arrhythmias in patients with an apparently normal heart. It mostly affects men of Asian descent, and the prevalence varies between ethnicities. Typical ECG abnormalities with no symptoms are referred to as the Brugada pattern, and hypothyroidism is a potential trigger of this.
View Article and Find Full Text PDFJACC Case Rep
September 2025
Cardiovascular Diseases Section, Interdisciplinary Department of Medicine (DIM), University of Bari "Aldo Moro," Bari, Italy.
Background: Brugada syndrome (BrS) is a rare inherited arrhythmia disease carrying a variable risk of sudden cardiac death. Diagnosis requires the type 1 Brugada electrocardiographic pattern, which can either be spontaneous or induced by sodium channel-blocking drugs. Ranolazine is an antianginal drug acting on the late sodium current with emerging antiarrhythmic properties; no information is available on the safety of ranolazine use in patients with BrS.
View Article and Find Full Text PDFBiochem Biophys Res Commun
September 2025
CERVO Brain Research Centre, Quebec City, QC, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada. Electronic address:
Brugada syndrome is a rare inherited cardiac arrhythmia disorder primarily characterized by ventricular fibrillation, which can lead to sudden cardiac death. It follows an autosomal dominant pattern of inheritance and is most associated with dysfunction of the cardiac sodium channel Nav1.5.
View Article and Find Full Text PDFCureus
July 2025
Private Practice, Humanis Dental Center, Perugia, ITA.
Brugada syndrome (BrS) is a rare inherited cardiac condition associated with a heightened risk of malignant arrhythmias, particularly during exposure to various pharmacological agents, including certain local anesthetics with sodium channel-blocking properties. This condition often generates significant concern among dental professionals, as the routine use of local anesthetics raises uncertainty about safety protocols and perceived medico-legal risks, frequently leading to patient refusal. The result is a silent yet systematic exclusion of these patients from standard pathways of care, with implications that extend beyond the clinical domain to encompass ethical, deontological, and social dimensions.
View Article and Find Full Text PDF